Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.
Randon G, Maddalena G, Germani MM, Pircher CC, Manca P, Bergamo F, Giordano M, Sposetti C, Montagna A, Vetere G, Zambelli L, Rasola C, Boccaccino A, Pagani F, Ambrosini M, Massafra M, Fontanini G, Milione M, Fassan M, Cremolini C, Lonardi S, Pietrantonio F. Randon G, et al. Among authors: bergamo f. JCO Precis Oncol. 2022 Apr;6:e2200037. doi: 10.1200/PO.22.00037. JCO Precis Oncol. 2022. PMID: 35544729 Free PMC article.
Chemotherapy for operable and advanced colorectal cancer.
Aschele C, Bergamo F, Lonardi S. Aschele C, et al. Among authors: bergamo f. Cancer Treat Rev. 2009 Oct;35(6):509-16. doi: 10.1016/j.ctrv.2009.04.003. Epub 2009 May 29. Cancer Treat Rev. 2009. PMID: 19481872 Review.
Hepatoid adenocarcinoma of the colon: what should we target?
Cappetta A, Bergamo F, Mescoli C, Lonardi S, Rugge M, Zagonel V. Cappetta A, et al. Among authors: bergamo f. Pathol Oncol Res. 2012 Jan;18(1):93-6. doi: 10.1007/s12253-011-9424-5. Epub 2011 Jun 12. Pathol Oncol Res. 2012. PMID: 21667305 Free article.
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A. Fornaro L, et al. Among authors: bergamo f. Ann Oncol. 2013 Aug;24(8):2062-7. doi: 10.1093/annonc/mdt165. Epub 2013 May 10. Ann Oncol. 2013. PMID: 23666916 Free article. Clinical Trial.
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, Michelucci A, Pfanner E, Brunetti I, Lupi C, Antoniotti C, Bergamo F, Lonardi S, Zagonel V, Simi P, Fontanini G, Falcone A. Loupakis F, et al. Among authors: bergamo f. Eur J Cancer. 2014 Jan;50(1):57-63. doi: 10.1016/j.ejca.2013.08.024. Epub 2013 Oct 15. Eur J Cancer. 2014. PMID: 24138831 Clinical Trial.
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Vivaldi C, Belli C, Bergamo F, Lutrino SE, Filippi R, Russano M, Vaccaro V, Brunetti AE, Rotella V, Falcone A, Barbera MA, Corbelli J, Fasola G, Aglietta M, Zagonel V, Reni M, Vasile E, Brandi G. Fornaro L, et al. Among authors: bergamo f. Br J Cancer. 2014 Apr 29;110(9):2165-9. doi: 10.1038/bjc.2014.190. Epub 2014 Apr 8. Br J Cancer. 2014. PMID: 24714745 Free PMC article.
Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A. Schirripa M, et al. Among authors: bergamo f. Int J Cancer. 2015 Jan 1;136(1):83-90. doi: 10.1002/ijc.28955. Epub 2014 May 28. Int J Cancer. 2015. PMID: 24806288 Free article.
203 results